Company intelligence / Profile preview
Alopexx Oncology, LLC
Concord, Massachusetts, United Statesprnewswire.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Alopexx Oncology has developed DI-Leu16-IL2, an immunocytokine that has been tested in Phase 1/2 clinical trials for B-cell Non-Hodgkin Lymphoma. The company has completed dose-escalation studies to determine safety, tolerability, pharmacokinetics, and clinical activity in patients with CD20 positive NHL who failed standard rituximab-containing therapy[4].
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodyImmunocytokine
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Beijing Shenogen Pharma (licensing agreement for development and commercialization of DI-Leu16-IL2 in China and other parts of Asia)[10]
Beyond the preview
Go deeper on Alopexx Oncology, LLC.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alopexx Oncology, LLC.